JFB-26550-80918
2 vaccinations
2 coded responses
2 check-ins
2 free-text entries
0 call cases
- Sex
- Male
- Age at first dose
- 05-11
- ZIP prefix
- 605 / IL
- Registered
- 2022-01-28
- Relationship
- Child or adolescent in my care
- Guardian
- DSC-14278-28839
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-11-11
Dose 1 — Pfizer-BioNTech
-
2021-12-04
Dose 2 — Pfizer-BioNTech
-
2022-01-28
Registered in v-safe
-
2022-03-05
Survey response — 3 months, dose 2, dependentMedDRA: COVID-19, Nasopharyngitis — Feeling: Good · Be unable to work or attend schoolFree text: Miles developed COVID and had cold-like symptoms.MedDRA releases: 2024-11 · check-in free text available
-
2022-06-04
Survey response — 6 months, dose 2, dependentMedDRA: Nasopharyngitis, Rhinorrhoea, SARS-CoV-2 test negative — Feeling: GoodFree text: Miles had cold-like symptoms (sniffles/runny nose), but he was negative for COVID.MedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-11-11 | Pfizer-BioNTech | No |
| 2 | 2021-12-04 | Pfizer-BioNTech | No |
Free text
Release 11 — 3 months, dose 2, dependent
Symptoms: Miles developed COVID and had cold-like symptoms.
Release 11 — 6 months, dose 2, dependent
Symptoms: Miles had cold-like symptoms (sniffles/runny nose), but he was negative for COVID.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | COVID-19 | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | SARS-CoV-2 test negative | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release